News
Public · Published
NBIX: Revenue rose 41% YoY as INGREZZA guidance increased and the pipeline advanced toward 2027 readouts
Neurocrine Biosciences reported Q3 revenue of $1.123B, up 41% year over year, and non-GAAP net income of $346.7M. It raised its full-year 2026 sales guidance for INGREZZA and anticipates nine pipeline readouts in 2027, meaning updates on drug-development studies.
Published:
Updated:
What happened
Neurocrine Biosciences reported Q3 revenue of $1.123B, up 41% year over year, and non-GAAP net income of $346.7M. It raised its full-year 2026 sales guidance for INGREZZA and anticipates nine pipeline readouts in 2027, meaning updates on drug-development studies.
Confirmed
Global impact / market context
Higher revenue and earnings show stronger reported business results, while increased INGREZZA guidance points to a higher sales outlook for the drug. The 2027 study updates could influence expectations for future products, but their commercial value depends on what the results show.
Analyst inference
The article gives no share-price reaction, prior guidance level, or detail on the expected study results. Investors therefore have evidence of recent growth and a raised sales outlook, but cannot assess the size of the guidance change or the pipeline’s likely contribution from this information alone.
Analyst inference
What to watch
- Look for the exact revised INGREZZA sales guidance and the assumptions behind it; sales falling short of that outlook could weaken expected revenue growth. Analyst inference
- Track the nine anticipated 2027 pipeline readouts, including their timing and results, because study outcomes may shape expectations for future drug sales. Confirmed
- Compare later revenue and non-GAAP net income with this quarter’s results to see whether growth continues and whether earnings rise alongside sales. Analyst inference
Evidence
- Original source link unavailable